Palantir Technologies has entered into a new partnership with Microsoft Corporation to deliver enhanced cloud, artificial intelligence (AI), and analytics capabilities to the US defence and intelligence agencies. The expanded collaboration will enable the firm to deploy its products, including Foundry, Gotham, Apollo, and AIP, in Microsoft’s cloud products designed for security operations. According to a press statement, the suite of products will be deployed in Microsoft Azure Government and in the Azure Government Secret (DoD Impact Level 6) and Top Secret clouds.
“Bringing Palantir and Microsoft capabilities to our national security apparatus is a step change in how we can support the defence and intelligence communities,” said the firm’s chief technology officer, Shyam Sankar. “Palantir AIP has pioneered the approach to operationalising AI value – beyond chat — across the enterprise. It’s our mission to deliver this software advantage and we’re thrilled to be the first industry partner to deploy Microsoft Azure OpenAI Service in classified environments.”
Palantir-Microsoft deal will see former more deeply embedded in government IT
Palantir will also become an early adopter of Azure’s OpenAI Service in Microsoft’s Secret and Top Secret environments. This integration will enable security organisations to develop AI-driven operational workloads for logistics, contracting, and action planning across defence and intelligence verticals. The services will become available after the completion of necessary authorisation and accreditation by appropriate government agencies.
“This expanded partnership between Microsoft and Palantir will help accelerate the safe, secure, and responsible deployment of advanced AI capabilities for the US government,” said Microsoft Americas president Deb Cupp.
As part of the collaboration, Palantir Federal Cloud Service are authorised to deploy on Microsoft Azure for IL5 environments. The two firms have also agreed to provide the defence and intelligence communities with training sessions to trial the technology.
Read more: Why can’t the NHS quit Palantir?
